Tranzyme Pharma (NASDAQ:TZYM) can measure the phase 3 clinical trial failure of its gastrointestinal drug ulimorelin by counting hours. The preliminary results don’t suggest that the compound did not work at all. Rather, post-surgical hospital care has apparently improved recovery time quite a bit. Time, more specifically time saved, has always been a focus for […]
Bristol-Myers Squibb (NYSE:BMY) is extending a drug discovery and development agreement with Tranzyme Pharma (NASDAQ:TZYM) to buy more time to continue the search for new drug candidates. Durham, North Carolina-based Tranzyme is entitled to up to $80 million in milestone payments for each drug program that results from the collaboration that is now set to […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Gilead Sciences (NASDAQ:GILD) executive Dr. Franck Rousseau has been named chief medical officer of gastrointestinal drug development company Tranzyme Pharma (NASDAQ:TZYM). Rousseau will oversee Durham, North Carolina-based Tranzyme’s drug portfolio including two clinical-stage candidates ulimorelin and TZP-102. Ulimorelin is studied in a phase 3 clinical trial as a drug that can help restore GI function […]
Gastrointestinal drug development company Tranzyme Pharma (NASDAQ:TZYM) is searching for a chief medical officer to replace a departing executive. After the close of the markets, Tranzyme announced that Dr. Gordana Kosutic, Tranzyme’s vice president of clinical and regulatory affairs, is resigning effective Sept. 30 “to pursue another opportunity.” No other details on Kosutic’s new position […]